Chinese biopharmaceutical company RemeGen Co., Ltd. (SHA:688331, HKG:09995) announced on Friday that it has received clearance from the United States Food and Drug Administration to initiate Phase II clinical trials for its bispecific antibody RC148.
RC148 is a novel bispecific antibody designed for the treatment of multiple advanced malignant solid tumours targeting both PD-1 and VEGF. It was developed using RemeGen's proprietary bispecific antibody technology platform.
Clinical trials for RC148, both as a monotherapy and in combination treatments, are currently ongoing in China.
FDA approval to proceed with US trials represents a major milestone in RC148's global clinical development strategy.
Novartis reports positive Phase III results for ianalumab in Sjögren's disease
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
Akeso doses first patient in Phase III Ivonescimab small cell lung cancer trial
Polymer Factory-led study advances nanocarrier-based drug delivery for aggressive cancers
RemeGen receives FDA approval to advance RC148 into Phase II trials for solid tumours
Spinogenix reports positive first cohort results from Phase 2a trial in Alzheimer's disease
Sebela Pharmaceuticals completes tegoprazan Phase 3 TRIUMpH programme in GERD with positive results
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Sanofi completes USD470m acquisition of Vigil Neuroscience
Sanyou Bio wins 'Best Customer Satisfaction CRO Award'
Kowa begins Phase 3 safety trial of Nicox's NCX 470 in Japan, triggering EUR2m milestone
MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241